Table 3.
Clinical Cure at Test of Cure by Pathogen: Microbiological Intention-to-Treat Population
| Clinical Cure by Pathogena | Tedizolid, n/N (%) | Linezolid, n/N (%) | Difference (95% Confidence Interval) |
|---|---|---|---|
| Gram-positive pathogens | 96/178 (53.9) | 137/202 (67.8) | |
| Staphylococcus aureus | 86/166 (51.8) | 130/192 (67.7) | –15.9 (–26.0 to –5.8) |
| Methicillin-resistant S. aureus | 29/54 (53.7) | 45/69 (65.2) | –11.5 (–28.9 to 5.9) |
| Methicillin-susceptible S. aureus | 58/117 (49.6) | 86/128 (67.2) | –17.6 (–29.8 to –5.4) |
| Streptococcus pneumoniae | 13/16 (81.3) | 7/10 (70.0) | |
| Monomicrobial gram-positive pathogens | 55/86 (64.0) | 77/104 (74.0) | |
| Mixed infection | 42/94 (44.7) | 60/98 (61.2) | |
| Acinetobacter baumannii complex | 14/30 (46.7) | 25/40 (62.5) | |
| Escherichia coli | 6/15 (40.0) | 6/9 (66.7) | |
| Klebsiella pneumoniae | 11/24 (45.8) | 14/30 (46.7) | |
| Pseudomonas aeruginosa | 8/14 (57.1) | 10/14 (71.4) | |
| Other | 21/45 (46.7) | 29/40 (72.5) |
aLimited to pathogens with ≥10 isolates in 1 treatment group.